Additional identifiers
EudraCT number
ClinicalTrials.gov number
NCT00003998
Protocol/serial number
G57
Study information
Scientific title
Acronym
Study hypothesis
Not provided at time of registration
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Condition
Ovary
Intervention
1. Docetaxel 75 mg/m(2) + Carboplatin AUC repeated on day 22 for six cycles
2. Paclitaxel 175 mg/m(2) + Carboplatin AUC 5 repeated on day 22 for six cycles
Intervention type
Drug
Phase
Phase III
Drug names
carboplatin versus docetaxel
Primary outcome measures
Not provided at time of registration
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/01/1997
Overall trial end date
01/05/2000
Reason abandoned
Eligibility
Participant inclusion criteria
1. Histologically confirmed epithelial ovarian cancer
2. Female
3. At least 18 years old
4. Stage Ic-IV disease
5. Written informed consent
Participant type
Patient
Age group
Adult
Gender
Female
Target number of participants
Not provided at time of registration
Participant exclusion criteria
Not provided at time of registration
Recruitment start date
01/01/1997
Recruitment end date
01/05/2000
Locations
Countries of recruitment
United Kingdom
Trial participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
Sponsor information
Organisation
Cancer Research UK (CRUK) (UK)
Sponsor details
PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom
+44 (0)207 317 5186
kate.law@cancer.org.uk
Sponsor type
Charity
Website
Funders
Funder type
Industry
Funder name
Cancer Research UK
Alternative name(s)
CRUK
Funding Body Type
private sector organisation
Funding Body Subtype
other non-profit
Location
United Kingdom
Funder name
Rhone-Poulenc Rorer
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
1. 2004 results in http://www.ncbi.nlm.nih.gov/pubmed/15547181
Publication citations
-
Results
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, , Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma., J. Natl. Cancer Inst., 2004, 96, 22, 1682-1691, doi: 10.1093/jnci/djh323.